Intron A (Interferon alfa-2b, recombinant)

Detailed View: Safety Labeling Changes Approved By FDA Center for Biologics Evaluation and Research (CBER)  

May 2015

Summary View


Neuropsychiatric Disorders
  • edited...If psychiatric symptoms persist or worsen, or suicidal or homicidal ideation or aggressive behavior towards others is identified, discontinue treatment with INTRON A and follow the patient closely, with psychiatric intervention as appropriate. Narcotics, hypnotics, or sedatives may be used concurrently with caution and patients should be closely monitored until the adverse effects have resolved.
Gastrointestinal Disorders
  • added...INTRON A increases the risk of hepatic decompensation and death in patients with cirrhosis. Any patient developing liver function abnormalities during treatment should be monitored closely and if appropriate, treatment should be discontinued.


Laboratory Tests
  • added bullet...Monitor hepatic function with serum bilirubin, ALT (alanine transaminase), AST (aspartate aminotransferase), alkaline phosphatase, and LDH (lactate dehydrogenase) at 2, 8 and 12 weeks following initiation of INTRON A, then every 6 months while receiving INTRON A. Permanently discontinue INTRON A for evidence of severe (Grade 3) hepatic injury or hepatic decompensation (Child-Pugh score >6 [class B and C]).


Post Marketing Experience

Respiratory, Thoracic, and Mediastinal Disorders

  • pulmonary fibrosis added 


June 2012

Summary View


  • Updated in order to make it consistent with the Boxed Warning and Neuropsychiatric Disorders subsection under Warning section of the Package Insert.


Page Last Updated: 06/12/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English